Literature DB >> 16328269

Verapamil prevents, in a dose-dependent way, the loss of ChAT-immunoreactive neurons in the cerebral cortex following lesions of the rat nucleus basalis magnocellularis.

Miroljub Popović1, Maria Caballero-Bleda, Natalija Popović, Luis Puelles, Thomas van Groen, Menno P Witter.   

Abstract

In the present study we analysed the neuroprotective effect of the L-type voltage-dependent calcium channel antagonist verapamil on cholineacetyltransferase (ChAT)-immunoreactive neurons in the cerebral cortex of rats with bilateral electrolytic lesions of the nucleus basalis magnocellularis (NBM). Treatment with verapamil (1.0, 2.5, 5.0 and 10.0 mg/kg/12 h i.p.) started 24 h after NBM lesions and lasted 8 days. Animals were sacrificed on day 21 after NBM-lesions. The bilateral NBM-lesions produced significant loss of ChAT-immunoreactive neurons in frontal, parietal and temporal cortex. Although the number of ChAT-positive neurons was significantly higher in NBM-lesioned animals treated with verapamil at a dose of 2.5, 5.0 and 10.0 mg/kg than in saline treated ones, the most significant effect was obtained at a dose of 5 mg/kg. This is, to our knowledge, the first report showing an inverted U-shape mode of neuroprotective action of the calcium antagonist verapamil, at morphological level in this particular model of brain damage. The demonstrated beneficial effect of verapamil treatment suggests that the regulation of calcium homeostasis during the early period after NBM lesions might be a possible treatment to prevent neurodegenerative processes in the rat cerebral cortex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328269     DOI: 10.1007/s00221-005-0219-3

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  66 in total

Review 1.  Overview and perspective on the therapy of Alzheimer's disease from a preclinical viewpoint.

Authors:  G Pepeu
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2001-01       Impact factor: 5.067

Review 2.  Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease.

Authors:  Frank M LaFerla
Journal:  Nat Rev Neurosci       Date:  2002-11       Impact factor: 34.870

Review 3.  Functional expression and localization of P-glycoprotein at the blood brain barrier.

Authors:  Reina Bendayan; Gloria Lee; Moise Bendayan
Journal:  Microsc Res Tech       Date:  2002-06-01       Impact factor: 2.769

4.  Cholinergic systems in mammalian brain identified with antibodies against choline acetyltransferase.

Authors:  B H Wainer; A I Levey; E J Mufson; M M Mesulam
Journal:  Neurochem Int       Date:  1984       Impact factor: 3.921

Review 5.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

Review 6.  Biochemical aspects of neurodegeneration in human brain: involvement of neural membrane phospholipids and phospholipases A2.

Authors:  Akhlaq A Farooqui; Wei-Yi Ong; Lloyd A Horrocks
Journal:  Neurochem Res       Date:  2004-11       Impact factor: 3.996

7.  Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.

Authors:  S Yasar; M Corrada; R Brookmeyer; C Kawas
Journal:  Neurobiol Aging       Date:  2005-02       Impact factor: 4.673

8.  Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals.

Authors:  K Ueda; S Shinohara; T Yagami; K Asakura; K Kawasaki
Journal:  J Neurochem       Date:  1997-01       Impact factor: 5.372

9.  In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection.

Authors:  B T Stuiver; B R Douma; R Bakker; C Nyakas; P G Luiten
Journal:  Neurodegeneration       Date:  1996-06

10.  Spinal cord regeneration induced by a voltage-gated calcium channel agonist.

Authors:  Agahan Unlu; Nithya Hariharan; Bermans J Iskandar
Journal:  Neurol Res       Date:  2002-10       Impact factor: 2.448

View more
  5 in total

1.  Verapamil attenuates scopolamine induced cognitive deficits by averting oxidative stress and mitochondrial injury - A potential therapeutic agent for Alzheimer's Disease.

Authors:  Saravanaraman Ponne; Chinnadurai Raj Kumar; Rathanam Boopathy
Journal:  Metab Brain Dis       Date:  2019-11-05       Impact factor: 3.584

2.  Verapamil protects dopaminergic neuron damage through a novel anti-inflammatory mechanism by inhibition of microglial activation.

Authors:  Yuxin Liu; Yi-Ching Lo; Li Qian; Fulton Tim Crews; Belinda Wilson; Hui-Ling Chen; Hung-Ming Wu; Shih-Heng Chen; Ke Wei; Ru-Band Lu; Syed Ali; Jau-Shyong Hong
Journal:  Neuropharmacology       Date:  2010-10-13       Impact factor: 5.250

3.  Possible role of P-glycoprotein in the neuroprotective mechanism of berberine in intracerebroventricular streptozotocin-induced cognitive dysfunction.

Authors:  Anil Kumar; Jitendriya Mishra; Kanwaljit Chopra; Dinesh K Dhull
Journal:  Psychopharmacology (Berl)       Date:  2015-10-08       Impact factor: 4.530

4.  Verapamil Blocks Scopolamine Enhancement Effect on Memory Consolidation in Passive Avoidance Task in Rats.

Authors:  Verónica Giménez De Béjar; María Caballero Bleda; Natalija Popović; Miroljub Popović
Journal:  Front Pharmacol       Date:  2017-08-23       Impact factor: 5.810

Review 5.  Verapamil and Alzheimer's Disease: Past, Present, and Future.

Authors:  Natalija Popović; Nicanor Morales-Delgado; David Vidal Mena; Antonia Alonso; María Pascual Martínez; María Caballero Bleda; Miroljub Popović
Journal:  Front Pharmacol       Date:  2020-05-05       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.